Abstract
Despite the progress achieved in chemo- and radiotherapy, cancer is still a leading life-threatening pathology. In that sense, there is a need for novel therapeutic strategies based on our current knowledge of cancer biology. Among the phenotypical features of cancer cells, two of them are of particular interest: their nearly universal glycolytic phenotype and their sensitivity towards an oxidative stress, both resulting from the combination of high anabolic needs and hypoxic growth conditions. By using menadione (vitamin K3) and ascorbate (vitamin C), we took advantage of these features to develop an original approach that consists in the exposure of cancer cells to an oxidant insult. When used in combination, these compounds exhibit a synergistic action and are devoid of major toxicity in vivo. Thus, this review is dedicated to the analysis of the molecular pathways by which this promising combination exerts its antitumoural effect.
Keywords: Ascorbate, menadione, cancer, oxidative stress, glycolysis, cell death
Current Molecular Pharmacology
Title: Targeting Cancer Cells by an Oxidant-Based Therapy
Volume: 1
Author(s): P. Buc Calderon, J. Verrax and H. Taper
Affiliation:
Keywords: Ascorbate, menadione, cancer, oxidative stress, glycolysis, cell death
Abstract: Despite the progress achieved in chemo- and radiotherapy, cancer is still a leading life-threatening pathology. In that sense, there is a need for novel therapeutic strategies based on our current knowledge of cancer biology. Among the phenotypical features of cancer cells, two of them are of particular interest: their nearly universal glycolytic phenotype and their sensitivity towards an oxidative stress, both resulting from the combination of high anabolic needs and hypoxic growth conditions. By using menadione (vitamin K3) and ascorbate (vitamin C), we took advantage of these features to develop an original approach that consists in the exposure of cancer cells to an oxidant insult. When used in combination, these compounds exhibit a synergistic action and are devoid of major toxicity in vivo. Thus, this review is dedicated to the analysis of the molecular pathways by which this promising combination exerts its antitumoural effect.
Export Options
About this article
Cite this article as:
Calderon Buc P., Verrax J. and Taper H., Targeting Cancer Cells by an Oxidant-Based Therapy, Current Molecular Pharmacology 2008; 1 (1) . https://dx.doi.org/10.2174/1874467210801010080
DOI https://dx.doi.org/10.2174/1874467210801010080 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Combinatorial Protein Biochemistry for Therapeutics and Proteomics
Current Pharmaceutical Biotechnology The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry The gp130 Receptor Cytokine Family: Regulators of Adipocyte Development and Function
Current Pharmaceutical Design Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas
Current Pharmaceutical Design Gene Therapy for Brain Cancer: Combination Therapies Provide Enhanced Efficacy and Safety
Current Gene Therapy Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy
Current Molecular Medicine The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Pharmacology and Therapeutic Applications of Enediyne Antitumor Antibiotics
Current Molecular Pharmacology Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Lessons from Viruses: Controlling the Function of Transmembrane Proteins by Interfering Transmembrane Helices
Current Medicinal Chemistry Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Modifications in the upper or Velbenamine Part of the Vinca Alkaloids have Major Implications for Tubulin Interacting Activities
Current Pharmaceutical Design Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-<i>Cas13a</i>
Current Gene Therapy